1 |
Martin A, Hancox RJ, Chang CL, Beasley R, Wrobel J, McDonald V, Dobler CC, Yang IA, Farah CS, Cochrane B, Hillis GS, Scowcroft CP, Aggarwal A, Di Tanna GL, Balicki G, Galgey S, Jenkins C. Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. BMJ Open 2021;11:e053446. [PMID: 34452971 DOI: 10.1136/bmjopen-2021-053446] [Reference Citation Analysis]
|
2 |
Shi Y, Zhang J, Huang Y. Prediction of cardiovascular risk in patients with chronic obstructive pulmonary disease: a study of the National Health and Nutrition Examination Survey database. BMC Cardiovasc Disord 2021;21:417. [PMID: 34470611 DOI: 10.1186/s12872-021-02225-w] [Reference Citation Analysis]
|
3 |
Bhutani M, Price DB, Winders TA, Worth H, Gruffydd-Jones K, Tal-Singer R, Correia-de-Sousa J, Dransfield MT, Peché R, Stolz D, Hurst JR. Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. Adv Ther 2022;39:2302-22. [PMID: 35482251 DOI: 10.1007/s12325-022-02137-x] [Reference Citation Analysis]
|
4 |
Qiu Y, Wang Y, Shen N, Wang Q, Chai L, Wang J, Zhang Q, Chen Y, Liu J, Li D, Chen H, Li M. Nomograms for Predicting Coexisting Cardiovascular Disease and Prognosis in Chronic Obstructive Pulmonary Disease: A Study Based on NHANES Data. Can Respir J 2022;2022:5618376. [PMID: 35721788 DOI: 10.1155/2022/5618376] [Reference Citation Analysis]
|